JD Health InternationalFRA:8ZN +1.61%90 EBITDA Margin % is 8.32% as of Dec. 2025, which is 117% above its 10-year median of 3.83. GuruFocus rates FRA:8ZN with a GF Score™ of 90/100 and a GF Value™ of €6.38 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 668 Healthcare Providers & Services companies, JD Health International ranks worse than 55.84% on this metric.
JD Health International (FRA:8ZN) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
JD Health International EBITDA Margin % Related Terms
JD Health International EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JD Health International EBITDA Margin % Competitor Comparison
For the Pharmaceutical Retailers subindustry, JD Health International's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JD Health International EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, JD Health International's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where JD Health International's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JD Health International (FRA:8ZN) has a EBITDA Margin % of 8.32% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JD Health International and its competitors. This is 117% above median its historical median of 3.83. According to the industry distribution chart, JD Health International ranks #373 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 55.8%.
Is JD Health International's EBITDA Margin % too high?
JD Health International's current EBITDA Margin % of 8.32% is 117% above median its 10-year median of 3.83. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. JD Health International's value of 8.32% is 18.5% below this industry median. Based on the distribution chart, JD Health International ranks #373 out of 668 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, JD Health International has a GF Score™ of 90/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JD Health International's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, JD Health International ranks #373 out of 668 companies for EBITDA Margin %. This places JD Health International in the lower half of its industry. The industry median EBITDA Margin % is 10.21. JD Health International's value of 8.32% is 18.5% below this benchmark. While the company's 10-year median is 3.83 vs. the industry median of 10.21, JD Health International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. JD Health International's current EBITDA Margin % of 8.32% is 18.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on JD Health International and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JD Health International's current EBITDA Margin % is 8.32%, which is 117% above median its own 10-year median of 3.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JD Health International stock overvalued right now?
Based on GuruFocus' analysis, JD Health International (FRA:8ZN) is currently considered Significantly Undervalued. The stock's GF Value™ is €6.38, compared to a current price of €3.72 — trading 41.7% below its estimated fair value. The current EBITDA Margin % is 8.32%, which is 117% above median its 10-year median of 3.83 and 18.5% below the Healthcare Providers & Services industry median of 10.21. JD Health International's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For JD Health International (FRA:8ZN), the current EBITDA Margin % is 8.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JD Health International (FRA:8ZN) Overvalued in 2026?
Based on GuruFocus' analysis, JD Health International stock appears to be undervalued.
The current stock price of €3.72 is trading 41.7% below its estimated GF Value™ of €6.38.
GuruFocus considers JD Health International to be Significantly Undervalued.
Key valuation signals for FRA:8ZN:
EBITDA Margin %: 8.32% (117% above median its 10-year median of 3.83)
GF Value™: €6.38 vs. price of €3.72 (41.7% below fair value)
Industry Position: 18.5% below the Healthcare Providers & Services median (#373 of 668)
No single metric tells the full story. See the FRA:8ZN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JD Health is the largest healthcare e-commerce platform in China in terms of revenue. The company offers pharmaceutical drugs and healthcare products on its platform, both as a marketplace that connects merchants to consumers and as a first-party, or 1P, direct retailer. It also offers online consultation from real life doctors and separately partners with offline pharmacies that can provide location-based 24/7 delivery as part of an omnichannel initiative to complement its core e-commerce business. Its closest competitors are Alibaba Health and Meituan for its e-commerce business. As of Dec. 31, 2024, the platform has over 200 million active annual users and over 70,000 merchants. JD Health is 67.49% owned by its parent company, JD.com.
90GF Score
Get the complete analysis for FRA:8ZN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:8ZN has been successfully added to your 
